<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736993</url>
  </required_header>
  <id_info>
    <org_study_id>PROLUNG001</org_study_id>
    <nct_id>NCT03736993</nct_id>
  </id_info>
  <brief_title>Metabolomics Predict Therapy Response</brief_title>
  <acronym>PROLUNG</acronym>
  <official_title>Towards Better Therapy for Resectable Lung Cancer: Metabolomics Predict Therapy Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complete resection is the mainstay of treatment for stage I-IIIA resectable non-small cell
      lung cancer (NSCLC). However rates of recurrence of disease are high, with five-year survival
      rates ranging between 73% (stage IA) and 24% (stage IIIA). Therefore, a prognostic biological
      marker that stratifies between NSCLC patients whom surgery cures versus patients in whom
      surgery would be futile due to early disease relapse after surgery is eagerly awaited.

      The primary objective of this prospective study is to establish a prognostic marker of early
      disease progression after complete surgical resection in patients with stages I to IIIA
      NSCLC. For this purpose the investigator will compare the metabolic profile with disease
      progression or death within one year after complete surgical resection to the patients with a
      progression free survival. Furthermore the investigator will evaluate the changes in the
      metabolic profile after surgery and if changes in this metabolic profile over time can
      predict disease recurrence before it becomes clinically apparent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Precision medicine relies on validated biomarkers that can accurately classify
      patients by their probable disease risk, prognosis and/or response to treatment. Metabolomics
      is particularly promising for biomarker development because altered metabolism is considered
      a hallmark of cancer. The measurement of the metabolomic plasma profile is cheap (+-50 EUR)
      and fast (+-17 min), with a high information throughput on a per sample base.

      Rationale: Complete resection is the mainstay of treatment for stage I-IIIA resectable
      non-small cell lung cancer (NSCLC). However rates of recurrence of disease are high, with
      five-year survival rates ranging between 73% (stage IA) and 24% (stage IIIA). Therefore, a
      prognostic biological marker that stratifies between NSCLC patients whom surgery cures versus
      patients in whom surgery would be futile due to early disease relapse after surgery is
      eagerly awaited.

      Study objective: The primary study hypothesis is that the metabolic plasma profile is a
      predictive marker of early disease progression after complete surgical resection in patients
      with pathological stages I to IIIA NSCLC. The secondary study hypothesis is that the level of
      dissimilarity between the metabolic profile before surgery and the metabolic profile after
      surgery, is a predictor for disease recurrence (in which the extreme case would be, that a
      normalization of the metabolic profile to the profile of a healthy person, is indicative of a
      good prognosis).

      Study design: Prospective, interventional design

      Study population: Stage I-IIIA NSCLC patients who will undergo complete surgical resection
      willing to provide a written informed consent.

      Number of patients: 200 patients with stage I-IIIA NSCLC who will undergo thoracic surgery
      with a curative intent will be included.

      Main study parameters/endpoints: Recurrence free survival, overall survival, metabolic
      phenotype, presence or absence of hot-spot mutations in tested proto-oncogenes and tumor
      suppressor genes in circulating tumor DNA (ctDNA) in blood plasma, the tumor tissue and
      possibly positive lymph nodes, 43 items of the EORTC quality of life questionnaire C30 and
      LC13.

      Nature and extent of the burden and risks associated with participation: Subjects will be
      asked to give consent to take 10-30 ml of blood at several moments throughout the disease
      course and in follow-up. Furthermore, the participants need to give their permission to use
      the resected tumor/lymph node tissue for genetic testing. Clinical parameters will be pooled
      in a database in a confidential way.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR)</measure>
    <time_frame>baseline</time_frame>
    <description>The metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) spectroscopy predicts disease disease recurrence within one year after surgical resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR)</measure>
    <time_frame>screening, day 1, week 1, week 4, week 6, week 12, week 52</time_frame>
    <description>The degree of change in the metabolic profile in plasma before and after surgery correlates with the risk for early disease recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ctDNA mutations in plasma</measure>
    <time_frame>day 1, week 12, week 52</time_frame>
    <description>The degree of change in ctDNA mutations in plasma before and after surgery correlates with the risk for early disease recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between presence or absence Hotspot mutations and the metabolic profile in plasma</measure>
    <time_frame>day 1, week 12, week 52</time_frame>
    <description>A specific metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) spectroscopy correlates with the presence of absence of certain ctDNA mutations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile of the primary tumor</measure>
    <time_frame>day 1</time_frame>
    <description>The metabolic profile of the primary tumor correlates with the metabolic profile in plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>NSCLC, Stage IIIA</condition>
  <arm_group>
    <arm_group_label>Additional blood sampling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional blood sampling</intervention_name>
    <description>Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.</description>
    <arm_group_label>Additional blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a stage I-IIIA NSCLC tumor, eligible to undergo surgery

          2. Signed written informed consent

        Exclusion Criteria:

          1. No fasting starting from 22:00 h the day prior to blood sampling

          2. Medication intake in the morning of the blood sampling

          3. Non-controlled diabetes

          4. History of cancer during the past 5 years

          5. Treatment for cancer during the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel Thomeer, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elien Dervaux, drs.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liesbet Mesotten, prof. dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>peter Adriaensens, prof. dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michiel Thomeer, prof. dr.</last_name>
    <phone>+32 89 32 15 12</phone>
    <email>michiel.thomeer@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elien Dervaux, drs.</last_name>
    <phone>+32 89 32 15 12</phone>
    <email>elien.derveaux@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilse Claessens</last_name>
      <phone>053724502</phone>
      <email>ilse.claessens@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Kurt Tournoy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piet Vercauter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michiel Thomeer, prof.dr.</last_name>
      <phone>+32 89 32 15 12</phone>
      <email>michiel.thomeer@uhasselt.be</email>
    </contact>
    <contact_backup>
      <last_name>Elien Dervaux, drs</last_name>
      <phone>+32 89 32 15 12</phone>
      <email>elien.dervaux@uhasselt.be</email>
    </contact_backup>
    <investigator>
      <last_name>Michiel Thomeer, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liesbet Mesotten, prof. dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Vermaelen, MD, PhD</last_name>
      <phone>093322815</phone>
      <email>karim.vermaelen@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Veerle Surmont, MD, PhD</last_name>
      <phone>093322815</phone>
      <email>veerle.surmont@ugent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Karim Vermaelen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veerle Surmont, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingel Demedts, MD, PhD</last_name>
      <phone>051237216</phone>
      <email>Ingel.Demedts@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Ingel Demedts, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Louis E, Cantrelle FX, Mesotten L, Reekmans G, Bervoets L, Vanhove K, Thomeer M, Lippens G, Adriaensens P. Metabolic phenotyping of human plasma by (1) H-NMR at high and medium magnetic field strengths: a case study for lung cancer. Magn Reson Chem. 2017 Aug;55(8):706-713. doi: 10.1002/mrc.4577. Epub 2017 Feb 27.</citation>
    <PMID>28061019</PMID>
  </reference>
  <reference>
    <citation>Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmüller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R; for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative. Metabolomics enables precision medicine: &quot;A White Paper, Community Perspective&quot;. Metabolomics. 2016;12(10):149. Epub 2016 Sep 2.</citation>
    <PMID>27642271</PMID>
  </reference>
  <reference>
    <citation>Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013 Jul 5;3(3):552-74. doi: 10.3390/metabo3030552.</citation>
    <PMID>24958139</PMID>
  </reference>
  <results_reference>
    <citation>Louis E, Adriaensens P, Guedens W, Bigirumurame T, Baeten K, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, Shkedy Z, Mesotten L, Thomeer M. Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. J Thorac Oncol. 2016 Apr;11(4):516-23. doi: 10.1016/j.jtho.2016.01.011. Epub 2016 Feb 29.</citation>
    <PMID>26949046</PMID>
  </results_reference>
  <results_reference>
    <citation>Louis E, Adriaensens P, Guedens W, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, de Jonge E, Thomeer M, Mesotten L. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016 Jan;27(1):178-84. doi: 10.1093/annonc/mdv499. Epub 2015 Oct 20.</citation>
    <PMID>26487580</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 27, 2019</last_update_submitted>
  <last_update_submitted_qc>July 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Prof. dr. Michiel Thomeer</investigator_full_name>
    <investigator_title>Head of department of respiratory medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>still no plan for, but open for sharing after discussion with participating groups</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

